CAPRICOR THERAPEUTICS, INC. 8-K

What Happened Capricor Therapeutics announced on May 7, 2026 that it filed a Complaint for Equitable Relief and an Application for a Preliminary Injunction in the Superior Court of New Jersey (Chancery Division, Bergen County). The lawsuit names Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma (collectively “NS”) and challenges the Commercialization and Distribution Agreement dated January 24, 2022, regarding the U.S. distribution of Capricor’s product Deramiocel. Capricor alleges a fundamental pricing flaw in the agreement and that NS failed to adequately prepare for the U.S. commercial launch, materially breaching the contract.

Key Details

• Filing date: Complaint and preliminary injunction filed May 7, 2026 in Superior Court of New Jersey (Chancery Division, Bergen County).
• Agreement at issue: Commercialization and Distribution Agreement between Capricor and Nippon Shinyaku dated Jan 24, 2022.
• Parties named: Capricor Therapeutics vs. Nippon Shinyaku Co., Ltd. and NS Pharma (U.S. subsidiary).
• Relief sought: rescission of the U.S. Distribution Agreement; declaratory judgment that Capricor may distribute Deramiocel directly or via other distributors; preliminary injunctive relief and other equitable remedies.

Why It Matters This legal action directly affects how Deramiocel may be commercialized and distributed in the U.S. If the court grants rescission or other relief, Capricor could regain the right to sell or appoint new distributors for Deramiocel, which would materially affect future revenue paths and commercialization timing. The suit also introduces legal and operational uncertainty—investors should note potential impacts on launch timing, costs, and partnership revenue. The filing contains forward-looking statements and Capricor refers investors to its SEC filings for related risk factors.